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Letter to the Editor
Detection of alphafetoprotein-expressing cells in the
blood of patients with hepatoma and hepatitis
Sir,
We read with great interest the article by Jiang et al (1997). Their
findings may have a significant impact on studies predicting
recurrence and metastasis of hepatocellular carcinoma (HCC) by
detecting alphafetoprotein (AFP) mRNA in circulating cells
(Komeda et al, 1995; Wong et al, 1997). They detected positive
AFP mRNA in 7 of 13 (53.8%) samples from patients with
hepatitis. As most HCC develops in a background of chronic
hepatitis B, the positive AFP mRNA detected in HCC patients
may have originated from either circulating normal hepatocytes or
HCC cells, or both.
The positive detection rate of AFP mRNA in the 20 HCC
patients is extremely high (95%). The authors attribute this to the
advanced disease involving either multiple intrahepatic foci (in 11
patients), large size of the primary tumours or distant metastasis
(in one patient), in 90% of the patients. However, we were
surprised that the authors conclude that the two patients (nos. 11
and 12) with a single small tumour had haematogenous spread of
HCC cells just because of the positive detection of AFP mRNA,
without mentioning any radiological or clinical evidence. From
the authors own evidence, it is possible that the signal detected
originated from normal hepatocytes. Certainly early spread of
small tumours is contrary to clinical and pathological experience.
Only one ofthe 20 HCC patients showed negative AFP mRNA,
and his serum AFP level was 4.5 ng ml-. The authors suggested
that the HCC cells of this patient may be expressing none or
extremely low levels ofAFP gene. It is noteworthy however that a
positive detection of AFP mRNA was found in a hepatitis patient
(no. 12) with an even lower serum level of AFP (3.5 ng ml-').
Furthermore, itis known thatthere is no directcorrelation between
levels of AFP mRNA and serum AFP (Di Bisceglie et al, 1986;
Nambu et al, 1995). In our studies, detection ofthe highest level of
AFP mRNA was in an HCC patient with normal serum AFP level
(< 10 ng ml-'), while only negligible levels of the gene product
were found to be associated with very high levels of serum AFP
(Wong et al, 1997).
Based on the above, we believe that it is premature to conclude,
from the results of their study, that haematogenous spreading of
HCC cells occurs very early. We agree with the authors that an
HCC-specific markergene in combination with nested polymerase
chain reaction is needed to confirm the malignant nature of AFP-
expressing cells circulating in the blood ofHCC patients.
S Ho andPJJohnson
Department ofClinical Oncology, Chinese University of
Hong Kong, Prince ofWales Hospital, Shatin, Hong Kong
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